Corbus Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat rare life-threatening inflammatory and fibrotic diseases. Its lead product candidate, Resunab, is a novel oral anti-inflammatory drug that is expected to commence Phase IIa clinical trials for the treatment of cystic fibrosis and diffuse systemic sclerosis diseases. The company is based in Norwood, Massachusetts.
Corbus Pharmaceuticals Holdings, Inc.
100 River Ridge Drive
Norwood, MA 02062
United States - Map
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Stock Message Board